IN THE CLAIMS:

Claims 1-5, 13-15, 19, and 32 have been amended herein. Claims 6 through 12, 18, 21 through 26, 29, and 31 are canceled without prejudice or disclaimer. Please note that all claims currently pending and under consideration in the referenced application are shown below. Please enter these claims as amended. This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

- 1. (Currently amended) A <u>vaccine</u> composition <u>comprising</u> free of whole <u>Eimeria</u> parasites, which comprises at least one protein or antigenic fragment thereof <u>and a pharmaceutically acceptable carrier</u>, wherein said <u>at least one protein or antigenic fragment in its native form:</u>
- (a) is present in the hydrophilic phase of a tertoctylphenoxypoly (ethoxyethanol) extract of total-Eimeria sporozoites; and
- (b) has a molecular mass of about 26-30 kDa as determined by SDS-PAGE under reducing conditions.
- 2. (currently amended) The <u>vaccine</u> composition according to claim 1, wherein said extract of *Eimeria* sporozoites is an extract of *E. tenella*, *E. acervulina*. *E. maxima*, *E. brunetti*, *E. necatrix* or *E. mitis* sporozoites.
- 3. (currently amended) The <u>vaccine</u> composition according to claim 1, wherein at least 50% w/w of proteinaceous material present is made up of one or more of said <u>at least one protein</u> proteins and/or <u>antigenic fragment fragments</u>.
- 4. (currently amended) The <u>vaccine</u> composition according to claim 1, wherein a plurality of said <u>at least one proteinproteins</u>, and/or <u>antigenic fragment fragments</u>-or variants thereof are present.

5. (currently amended) The <u>vaccine</u> composition according to claim 1, wherein only one of said at least one protein proteins or <u>antigenic fragment fragments</u> thereof is present.

6-12 (Canceled).

- 13. (currently amended) The vaccine composition according to claim 1, wherein said vaccine comprises an adjuvant.
- 14. (currently amended) The <u>vaccine</u> composition according to claim 13, wherein the adjuvant is Quil A.
- 15. (currently amended) The vaccine composition according to elaim 12 claim 1, which is in unit dosage form.

16-17 (canceled)

18. (Canceled)

- 19. (currently amended) An immunological reagent, comprising a protein, or <u>antigenic</u> fragment thereof which is bound to a support or provided with a detectable label wherein the protein or antigenic fragment in its native form:
- (a) is present in the hydrophilic phase of a tertoctylphenoxypoly (ethoxyethanol) extract of total

 <u>Eimeria</u> sporozoites; and
- (b) has a molecular mass of about 26-30 kDa as determined by SDS-PAGE under reducing conditions as described in claim-1,.

20. (canceled)

Claims 21-26 (canceled)

- 27. (previously presented) The vaccine composition according to claim 13, which is in unit dosage form.
- 28. (previously presented) The vaccine composition according to claim 14, which is in unit dosage form.

29. (canceled)

30. (previously presented) A test kit for the diagnosis of *Eimeria* infection, comprising an immunological reagent according to claim 19.

31. (canceled)

- 32. (currently amended) A method of making a vaccine composition, comprising admixing the composition according to claim 1-at least one protein or antigenic fragment, with one or more pharmaceutically acceptable carriers wherein said at least one protein or antigenic fragment in its native form:
- (a) is present in the hydrophilic phase of a tertoctylphenoxypoly (ethoxyethanol) extract of Eimeria sporozoites; and
- (b) has a molecular mass of about 26-30 kDa as determined by SDS-PAGE under reducing conditions.